Physician profile
Leonid Toprover
NPI 1174568596
$9,823.39
in general payments reported to CMS, 2019-2025
14 companies · $1,543 in 2025
The $1,543 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,575 · 2020: $785 · 2021: $576 · 2022: $1,683 · 2023: $1,212 · 2024: $450 · 2025: $1,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,204.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,709.25 | 2019-2025 | Linzess, Creon, Qulipta |
| Amgen INC. | $740.37 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $677.32 | 2019-2022 | |
| Allergan, INC. | $498.67 | 2019-2020 | |
| Pfizer INC. | $442.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $352.48 | 2022-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $250.00 | 2025 | Caplyta |
| Antares Pharma, INC. | $250.00 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $245.68 | 2023-2025 | Austedo Xr, Austedo |
| Medtronic, INC. | $155.25 | 2022 | |
| Sk Life Science, INC. | $144.22 | 2022 | |
| Idorsia Pharmaceuticals US INC | $124.99 | 2022 | |
| Alkermes, INC. | $120.00 | 2023 | Lybalvi |
| Neurelis, INC. | $112.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Toprover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.